Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjcard.2020.09.009 | DOI Listing |
ERJ Open Res
November 2024
Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, Hôpital Bicêtre, Service d'ORL, Le Kremlin-Bicêtre, France.
Background: Recurrent infections of the nose, sinuses and ears are common problems for people with primary ciliary dyskinesia. While pulmonary exacerbations in primary ciliary dyskinesia are defined, there is no definition for ear-nose-throat exacerbations, a potential outcome for research and clinical trials.
Methods: We set up an expert panel of 24 ear-nose-throat specialists, respiratory physicians, other healthcare professionals and patients to develop consensus definitions of sinonasal and otological exacerbations in children and adults with primary ciliary dyskinesia for research settings.
Neoplasia
January 2025
Institute of Physiology, University of Zurich, Switzerland; Comprehensive Cancer Center Zurich. Electronic address:
Microbiome
October 2024
Medical Microbiology Department, UMC Utrecht, Utrecht, The Netherlands.
Background: The intestinal microbiota plays a significant role in maintaining systemic and intestinal homeostasis, but can also influence diseases such as inflammatory bowel disease (IBD) and cancer. Certain bacterial species within the intestinal tract can chronically activate the immune system, leading to low-grade intestinal inflammation. As a result, plasma cells produce high levels of secretory antigen-specific immunoglobulin A (IgA), which coats the immunostimulatory bacteria.
View Article and Find Full Text PDFSports Med Open
July 2024
Faculty of Health, School of Sport, Exercise and Rehabilitation, Human Performance Research Centre, University of Technology Sydney, Ultimo, Sydney, NSW, 2007, Australia.
Background: High-Intensity Multimodal Training (HIMT) refers to all styles of high-intensity combined aerobic, resistance and/or bodyweight exercise. Previous heterogeneity in exercise prescription and reporting in HIMT reduces the understanding of which factors should be considered when prescribing HIMT (e.g.
View Article and Find Full Text PDFMol Ther Oncol
September 2024
Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Bispecific T cell engagers are a promising class of therapeutic proteins for cancer therapy. Their potency and small size often come with systemic toxicity and short half-life, making intravenous administration cumbersome. These limitations can be overcome by tumor-specific expression, allowing high local accumulation while reducing systemic concentrations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!